Marker Therapeutics Stock Book Value Per Share
| MRKR Stock | USD 1.15 0.04 3.36% |
Marker Therapeutics fundamentals help investors to digest information that contributes to Marker Therapeutics' financial success or failures. It also enables traders to predict the movement of Marker Stock. The fundamental analysis module provides a way to measure Marker Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Marker Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.44 | 1.51 | |
| Tangible Book Value Per Share | 1.44 | 1.51 |
Marker | Book Value Per Share |
Marker Therapeutics Company Book Value Per Share Analysis
Marker Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Marker Therapeutics Book Value Per Share | 0.83 X |
Most of Marker Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Marker Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Marker Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Marker Therapeutics is extremely important. It helps to project a fair market value of Marker Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Marker Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Marker Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Marker Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Marker Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
At this time, Marker Therapeutics' Common Stock Shares Outstanding is relatively stable compared to the past year.
In accordance with the recently published financial statements, the book value per share of Marker Therapeutics is about 0.835 times. This is 149.12% lower than that of the Biotechnology sector and 100.34% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.96% higher than that of the company.
Marker Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marker Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Marker Therapeutics could also be used in its relative valuation, which is a method of valuing Marker Therapeutics by comparing valuation metrics of similar companies.Marker Therapeutics is currently under evaluation in book value per share category among its peers.
Marker Fundamentals
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.42 | ||||
| Profit Margin | (1.80) % | ||||
| Operating Margin | (1.25) % | ||||
| Current Valuation | (5.38 M) | ||||
| Shares Outstanding | 10.71 M | ||||
| Shares Owned By Insiders | 9.85 % | ||||
| Shares Owned By Institutions | 41.80 % | ||||
| Number Of Shares Shorted | 149.81 K | ||||
| Price To Earning | (9.39) X | ||||
| Price To Book | 1.71 X | ||||
| Price To Sales | 2.54 X | ||||
| Revenue | 3.31 M | ||||
| Gross Profit | (5.6 M) | ||||
| EBITDA | (11.79 M) | ||||
| Net Income | (14.05 M) | ||||
| Cash And Equivalents | 18.08 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 3.07 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 1.99 X | ||||
| Book Value Per Share | 0.83 X | ||||
| Cash Flow From Operations | (16.44 M) | ||||
| Short Ratio | 1.80 X | ||||
| Earnings Per Share | (1.07) X | ||||
| Target Price | 10.33 | ||||
| Beta | 1.52 | ||||
| Market Capitalization | 13.71 M | ||||
| Total Asset | 17.13 M | ||||
| Retained Earnings | (436.29 M) | ||||
| Working Capital | 14.05 M | ||||
| Current Asset | 6.85 M | ||||
| Current Liabilities | 5.93 M | ||||
| Net Asset | 17.13 M |
About Marker Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marker Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marker Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marker Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.